Biopharma Execs Go Face-To-Face With Obama Over TPP
This article was originally published in PharmAsia News
President Barack Obama heard firsthand from a half dozen or so biopharmaceutical executives during an Oct. 8 White House face-to-face meeting about the industry's disappointment in the administration for agreeing to a minimum of five years of exclusivity protection for innovator biologics against biosimilars in the final TPP trade deal, rather than the 12 years required in the US by law.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.